IL2RA and graft versus host disease: Daclizumab (anti-Tac) is an antibody that binds to CD25 and mediates Treg depletion; this drug was used for the prevention of graft-vs-host disease and the treatment of relapsing multiple sclerosis prior to being withdrawn from the market in 2018 due to adverse events.31